Maravai LifeSciences Holdings Inc. Class A Common Stock vs Noble Corporation plc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Noble Corporation plc trades at $42.9 (market cap $6.85B). The key difference: Noble Corporation plc is far larger — about 7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Noble Corporation plc pays a 4.66% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Noble Corporation plc for 27 Days on average.
| MRVI | NE | |
|---|---|---|
Market Cap | $977.37M | $6.85B |
Volume | 2,742,564 | 984,361 |
Sector | Health | Energy |
52-Week High | $9.00 | $54.37 |
52-Week Low | $2.83 | $27.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $1.08B | $8.28B |
Dividend Yield | — | 4.66% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Noble Corporation (NE) trades at $43.42, up 1.12% today. The stock shows mixed signals with a bullish technical outlook but bearish moving averages. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 and Q4 2025 missing. Revenue declined from $3.3B in 2025 to $3.1B in 2026, and net income fell from $217M to $150M. Positive news includes a long-term drilling contract in Ghana, but the company faces an ongoing law firm investigation.
Outlook is cautious. The consensus price target of $52.00 implies potential upside, supported by a 'Buy' rating from 31% of analysts. However, declining profitability, mixed earnings history, and legal scrutiny present risks. Investors should weigh contract wins against fundamental pressures and sentiment headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →